Featured Research

from universities, journals, and other organizations

75 percent of patients taking popular blood-thinners on wrong dose: Millions at risk for uncontrolled bleeding or blood clots

Date:
November 6, 2012
Source:
Intermountain Medical Center
Summary:
Cardiology researchers have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study. This could put them at risk for serious problems like uncontrolled bleeding or developing blood clots.

Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.

This could put them at risk for serious problems like uncontrolled bleeding or developing blood clots.

Millions of Americans with coronary artery disease take one of the two drugs -- clopidogrel (Plavix) and prasugrel (Effient) -- to prevent harmful blood clots that can cause a stroke or heart attack. Current guidelines recommend that all patients take the same standardized dose. But in this new study of 521 patients, researchers at the Intermountain Medical Center Heart Institute found that dose is not effective for all patients.

"There's a sweet spot, an appropriate range for each patient. But we found that not many people are falling into that range," said cardiologist Brent Muhlestein, MD, a cardiac researcher at the Intermountain Medical Center Heart Institute.

Dr. Muhlestein is presenting the group's findings on Nov. 6 at the American Heart Association Scientific Sessions 2012 in Los Angeles.

"We showed that by performing a simple blood test to see whether or not the blood is clotting properly, we can determine whether patients are getting an appropriate, individualized dose of the medications," he says. "The test is easy to perform, but not widely used."

The Intermountain Medical Center Heart Institute study could help lead to personalized treatment and improved results for millions of people taking the drugs. It may also help cut pharmacy bills for many patients. The annual cost for one of the medications is more than $1,800. Finding the lowest effective dose for those patients could conceivably cut their bill in half.

Major findings of the study show that:

  • Half of patients taking clopidogrel were getting too little of the drug to prevent clotting most effectively. A quarter were getting too much. Only a quarter were getting an accurate dose.
  • Half of patients taking prasugrel are getting too much of the drug, which could lead to dangerous bleeding. A quarter were getting too little. Only a quarter are getting the appropriate dose.

The researchers also discovered that common indicators like age, gender, cholesterol levels, and history of heart problems were not good predictors for how a person would react to the drugs.

"That means there's not an easy way to predict how a person will react to these drugs. But the blood test is very effective," said Dr. Muhlestein. "In fact, a physician could have the test machine on his or her desk and perform the test right there in the office."


Story Source:

The above story is based on materials provided by Intermountain Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Intermountain Medical Center. "75 percent of patients taking popular blood-thinners on wrong dose: Millions at risk for uncontrolled bleeding or blood clots." ScienceDaily. ScienceDaily, 6 November 2012. <www.sciencedaily.com/releases/2012/11/121106125554.htm>.
Intermountain Medical Center. (2012, November 6). 75 percent of patients taking popular blood-thinners on wrong dose: Millions at risk for uncontrolled bleeding or blood clots. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2012/11/121106125554.htm
Intermountain Medical Center. "75 percent of patients taking popular blood-thinners on wrong dose: Millions at risk for uncontrolled bleeding or blood clots." ScienceDaily. www.sciencedaily.com/releases/2012/11/121106125554.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins